

RECENT ADVANCES AGAINST BLOOD CANCERS

In the 12 months from August 1, 2018 to July 31, 2019, the U.S. Food and Drug Administration made numerous decisions that are transforming the lives of patients with a wide array of hematologic cancers, including the following:

Acute Lymphoblastic Leukemia (ALL) in Adults

- Calaspargase pegol-mknl (Asparlas) is a chemotherapeutic approved in December 2018 for use as part of a multiagent cytotoxic chemotherapy regimen for children, adolescents, and young adults ages 1 month to 21 years.
- ClonoSEQ assay is a next-generation sequencing–based test approved in September 2018 for determining whether a patient has minimal residual disease, or very low levels of cancer cells remaining, after treatment.

Acute Myeloid Leukemia

- Glasdegib (Daurismo) is a molecularly targeted therapeutic approved in November 2018.
- Gilteritinib (Xospata) is a molecularly targeted therapeutic approved in November 2018.
- Venetoclax (Venclexta) is a molecularly targeted therapeutic approved in November 2018.

Blastic Plasmacytoid Dendritic Cell Neoplasm

- Tagraxofusp-erzs (Elzonris) is a molecularly targeted therapeutic approved in December 2018.

Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

- Duvelisib (Copiktra) is a molecularly targeted therapeutic approved in September 2018.

Cutaneous T-cell Lymphoma

- Mogamulizumab-kpkc (Poteligeo) is an immunotherapeutic approved in August 2018.

Diffuse Large B-cell Lymphoma

- Polatuzumab vedotin-piiq (Polivy) is a molecularly targeted therapeutic approved in June 2019.

Follicular Lymphoma

- Duvelisib (Copiktra) is a molecularly targeted therapeutic approved in September 2018.
- Lenalidomide (Revlimid) is an immunomodulatory agent approved in May 2019 for use in combination with the immunotherapeutic rituximab (Rituxan).

Hairy Cell Leukemia

- Moxetumomab pasudotox-tdfk (Lumoxiti) is a molecularly targeted therapeutic approved in September 2018.

Marginal Zone Lymphoma

- Lenalidomide is an immunomodulatory agent approved in May 2019 for use in combination with the immunotherapeutic rituximab.

Multiple Myeloma

- ClonoSEQ assay is a next-generation sequencing–based test approved in September 2018 for determining whether a patient has minimal residual disease, or very low levels of cancer cells remaining, after treatment.
- Selinexor (Xpovio) is a molecularly targeted therapeutic approved in July 2019 for use in combination with dexamethasone.

